Literature DB >> 11523258

Stability of human follicle-stimulating hormone receptor mRNA in stably transfected cells.

C Zhu1, H Tian.   

Abstract

In order to assess the impact of mRNA degradation on steady state levels of follicle-stimulating hormone receptor (FSHR) mRNA and on regulation of FSHR gene expression, the stability and half-life of FSHR mRNA were determined in transfected cells expressing recombinant FSHR. Time-dependent changes in FSHR mRNA content were determined by nuclease protection-solution hybridization assay (NPA) or by qualitative reverse transcription-competitive polymerase chain reaction (RT-PCR) in cultured hFSHR-YI cells, cell lines stably transfected with a human FSHR cDNA. FSHR mRNA content remained constant during 8 h control incubations of hFSHR-Y1 cells (NPA, 2.9 +/- 0.3 micrograms/mg RNA; RT-PCR, 2.7 +/- 0.3 micrograms/mg RNA). Actinomycin D (ActD, 5 micrograms/ml) inhibited mRNA synthesis, as assessed by incorporation of [3 H]uridine into total RNA, by 90% within 1 h in hFSHR-Y1 cells. No effect of ActD on cellular morphology or viability was observed. ActD caused a time-dependent decrease in FSHR mRNA content in hFSHR-Y1 cell lines with a lag time of 1 h. There were no significant differences in the rate of FSHR mRNA degradation between the two methods of mRNA quantification. The half-life of hFSHR mRNA was 3.6 +/- 0.2 h by NPA and 3.1 +/- 0.1 h by RT-PCR. The results indicated that degradation of mRNA was an important process in maintenance of steady state expression of the FSHR gene in cells stably expressing recombinant receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11523258     DOI: 10.1007/BF02888024

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  14 in total

1.  A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates.

Authors:  S Diviacco; P Norio; L Zentilin; S Menzo; M Clementi; G Biamonti; S Riva; A Falaschi; M Giacca
Journal:  Gene       Date:  1992-12-15       Impact factor: 3.688

2.  Transcriptional and post-transcriptional regulation of FSH receptor in rat granulosa cells by cyclic AMP and activin.

Authors:  M Tano; T Minegishi; K Nakamura; S Karino; Y Ibuki; K Miyamoto
Journal:  J Endocrinol       Date:  1997-06       Impact factor: 4.286

Review 3.  Messenger RNA degradation in eukaryotes.

Authors:  A B Sachs
Journal:  Cell       Date:  1993-08-13       Impact factor: 41.582

4.  cAMP stimulates transcription of the beta 2-adrenergic receptor gene in response to short-term agonist exposure.

Authors:  S Collins; M Bouvier; M A Bolanowski; M G Caron; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  Regulation of oncogene expression in cultured aortic smooth muscle cells. Post-transcriptional control of c-myc mRNA.

Authors:  M S Kindy; G E Sonenshein
Journal:  J Biol Chem       Date:  1986-09-25       Impact factor: 5.157

6.  A practical approach for quantitating specific mRNAs by solution hybridization.

Authors:  D M Durnam; R D Palmiter
Journal:  Anal Biochem       Date:  1983-06       Impact factor: 3.365

7.  A specific FSH receptor in rat granulosa cells: properties of binding in vitro.

Authors:  A Nimrod; G F Erickson; K J Ryan
Journal:  Endocrinology       Date:  1976-01       Impact factor: 4.736

8.  Decay of follicle-stimulating hormone-beta messenger RNA in the presence of transcriptional inhibitors and/or inhibin, activin, or follistatin.

Authors:  B Attardi; S J Winters
Journal:  Mol Endocrinol       Date:  1993-05

9.  A role for increased lutropin/choriogonadotropin receptor (LHR) gene transcription in the follitropin-stimulated induction of the LHR in granulosa cells.

Authors:  H Shi; D L Segaloff
Journal:  Mol Endocrinol       Date:  1995-06

10.  Quantification of androgen receptor and follicle-stimulating hormone receptor mRNA levels in human and monkey testes by a ribonuclease-protection assay.

Authors:  B Dankbar; M Sohn; E Nieschlag; J Gromoll
Journal:  Int J Androl       Date:  1995-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.